Pioneer in 3D/4D Medical Visualization Also Showcases Comprehensive Cardiac Platform with Customizable, Automated Workflows
NEWARK, Calif., March 2, 2023 /PRNewswire-PRWeb/ -- Ziosoft, a pioneer in 3D/4D AI medical visualization, will feature extracellular volume fraction (ECV) computed tomography (CT) and Revoras-enabled ECV cardiac magnetic resonance (CMR) analytical capabilities at the annual American College of Cardiology (ACC) conference being held March 4-6, 2023 in New Orleans. The Revoras software is the company's most recent development, offering a scalable, enterprise platform.
"Ziosoft's software enables accurate image intelligence along with a superb, stable algorithm," said Rajeev Taitriya, vice president of marketing and business development for Ziosoft. "These capabilities are designed to provide the foundation for reproducible and trusted outcomes that clinical decisions can be made upon – all available through our highly economical Zioflex subscription model."
Ziosoft's ECV-CT intuitive workflow adds a comprehensive analysis to structural heart CT scans. It provides protocols such as calcium scoring, coronary and transcatheter aortic valve replacement (TAVR) analysis. It is a noninvasive method to quantity myocardial interstitial volume in a range of heart diseases such as Amyloids. While imaging myocardial fibrosis using CT is still in the early stages, the future of ECV-CT could be considered a necessary tool as a potential imaging biomarker for myocardial fibrosis.
The Revoras software is Ziosoft's newest simplified platform with an improved GUI, along with several AI algorithms enhancements and novel applications such as ECV - CMR. This is a comprehensive solution for a one-stop-shop for cardiac MR studies. It offers viability, velocity and structural analysis including left/right ventricle (LV/RV) function, with and without papillaries, plus RV mass, all important for determining the viability of the overall volume and ejection fraction. In addition, the ECV-CMR software offers 2D flow with comparison load to measuring blood flow velocity, T1 and ECV mapping for fibrosis, TAVR analysis, as well as delayed enhancement to identify myocardial injury.
MRA Coronary analysis can be done with CMR protocol instead of an added CTA for coronary analysis, but also enables multi-data fusion for serial studies by merging CT and MR data for anatomic analysis and interventional/surgical planning.
"Ziosoft's next generation 3D/4D advanced visualization also provides virtual 3D images for printing 3D models for education, clinical resources and surgical planning," said Shusuke Chino, co-founder and president, Ziosoft. "We have more than 20 years of medical imaging expertise with deep learning to enable accurate evaluations with easy-to-use intuitive tools for efficient and customizable workflows, Our newest Revoras platform is based on this extensive experience and we look forward to creating more significant developments to expand our AI-enabled visualization platform in the future."
The Ziosoft platform provides a comprehensive, multi-modality applications for cardiac imaging needs. It is customizable with automated workflows to maximize efficiency. As a software-only platform, it is designed to minimize the cost of ownership. The Ziosoft platform also offers its unique PhyZiodynamics 3D/4D solution, as well as recently introduced Zioflex, a monthly subscription program designed to provide a risk-free introduction of Ziosoft's many AV clinical applications.
About Ziosoft.
Ziosoft provides a comprehensive multi-modality, 3D/4D advanced processing and viewing solution for a wide variety of specialties. Its customizable platform provides automated workflow to maximize efficiency. It is also a scalable, enterprise platform for "anywhere" accessibility and, as a software-only solution, it is simplified to minimize cost of ownership. Ziosoft is part of the Los Angeles-based Nantworks a consortium of companies led by Patrick Soon-Shiong, MD, the past founder of Abraxis BioScience, current CEO of Nantworks, founder, executive chairman and chief science officer for ImmunityBio. He is also the owner of the Los Angeles Times and San Diego Tribune. For further information on Ziosoft, visit http://www.ziosoftinc.com.
Media Contact
Laurie Hallwyler, Ziosoft, 1 6502489081, [email protected]
SOURCE Ziosoft
Share this article